Strides Pharma

Strides Pharma Q2FY26 results: Net profit jumps 82% to ₹131.5 crore

Strides Pharma Science Ltd on Friday reported an 82 per cent jump in consolidated net profit at Rs 131.52 crore in the second quarter ended September 30, 2025 on the back of strong revenue growth in 'other regulated markets' and lower expenses. The company had posted a consolidated net profit of Rs 72.3 crore in the corresponding period last fiscal, Strides Pharma Science said in a regulatory filing. Consolidated revenue from operations in the second quarter stood at Rs 1,220.83 crore as compared to Rs 1,166.93 crore in the year-ago period, it added. Total expenses in the quarter under review stood at Rs 1,085.03 crore as compared to Rs 1,104.61 crore in the same period last fiscal, the company said. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur said, "Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the 'other regulated markets'." In an investor presentation, the company said in Q2 FY26 'other ...

Stocks to watch today, Sep 9: Infosys, TVS Motor, RailTel Corp, IRB Infra

Stocks to watch on Tuesday, September 9: | TVS Motor Company: To pass on full benefit of GST rate cut across its ICE vehicle portfolio, effective September 22.

Strides enters into product partnership with Kenox for nasal spray

Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have ...

BSE Smallcap index hits 6-month high, recovers 35% from April low

In the past month, the Smallcap index gained 3 per cent, as against a 1.5 per cent rise in Midcap and a 0.66 up move in Sensex

Strides Pharma initiates Class-II recall of Testosterone Gel in US

The recall was voluntarily initiated by Strides Pharma on March 5, 2025, and remains ongoing. Consignees have been informed about this recall formerly, although public press release has not been issue

Strides Pharma Science share price gains 3% on demerger news; details here

The proposed structure, the company said, envisages the NewCo to be a WOS of Strides and there will not be any impact on Strides, financially or otherwise, arising out of the proposed restructuring

Strides Pharma gains 3% as Singapore arm acquires 100% stake in Amexel Pte

Amexel is a company incorporated under the laws of Singapore on March 22, 2023 and is yet to commence its operations

Strides Pharma rises 4% after NCLT nods creation of OneSource

Following this approval, OneSource will advance towards listing its equity shares on the BSE and NSE

Strides Pharma Q2 results: Net profit at Rs 93.7 cr, revenue up 20%

US revenue hitting quarterly high, sustained growth across markets among reasons

Strides Pharma CDMO arm gets Rs 801 cr from investors in pre-listing round

Strides Pharma Science on Wednesday said its associate firm has received equity commitment of Rs 801 crore from domestic and foreign institutional investors in the pre-listing round. OneSource Specialty Pharma, the contract development and manufacturing organisation (CDMO) arm of the company, has received confirmed capital infusion commitments from investors, Strides Pharma Science said in a statement. The share subscription agreements are being executed at a pre-money equity value of USD 1.65 billion, it added. The fundraise is in line with the scheme of arrangement announced in September 2023 and the investment is subject to customary closing conditions, including receipt of necessary regulatory approvals, the company said. "This fundraise will enable us to accelerate our growth plans, right-size our debt book, and commit significant new capex for a strong order book across our three platforms," Strides Group Founder Arun Kumar said. In September last year, Strides announced t

Strides Pharma Science gets USFDA nod for generic antidepressant tablets

Strides Pharma Science Ltd on Monday said its arm has received approval from the US health regulator for its generic version of antidepressant Fluoxetine tablets. The approval granted by the US Food & Drug Administration (USFDA) to wholly owned subsidiary Strides Pharma Global Pte. Ltd, Singapore, is for Fluoxetine tablets of strength 60 mg, Strides Pharma Science said in a regulatory filing. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine tablets, 60 mg, of TWi Pharmaceuticals, Inc, it added. The Fluoxetine tablets will be manufactured at the company's facility in Puducherry, Strides said. With the approval of the Fluoxetine Tabs 60 mg strength, the company is now positioned to offer a complete portfolio of Fluoxetine across capsules and tablets in 10 mg, 20 mg, and 60 mg strengths, it added. The addition of the Fluoxetine tablets 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of ...

Strides Pharma gets shareholders' nod to set up speciality pharma CDMO

Strides Pharma Science on Wednesday said it has received approval from shareholders and secured creditors for creation of OneSource -- a specialty pharma CDMO (contract development and manufacturing organization). The company has secured the approval of its shareholders and secured creditors with overwhelming majority, along with those of OneSource Specialty Pharma and SteriScience Specialties, in meetings convened under the guidance of the National Company Law Tribunal, it said in a regulatory filing. All the secured creditors who voted on the scheme for the three companies in their respective meetings were in favour of the scheme, it added. "We believe OneSource will unlock considerable value for Strides' stakeholders upon its listing. We remain committed to delivering on this promise and express our gratitude to our shareholders and creditors for their continued trust and support," Strides Pharma Science Executive Chairperson Arun Kumar said. In September 2023, Strides announced

Strides Pharma hits all time high after USFDA approval for this drug

Strides Pharma share price today reached its all time high at Rs 1394.95 per share on the BSE, rising as much as 3.79 per cent in Friday's intraday deals

Strides Pharma falls over 4% after USFDA gives VAI tag to Chennai facility

Strides Alathur facility caters to the US and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets

Strides Pharma reports profit of Rs 68.3 crore in Q1, revenue up 16%

As per the company statement, US revenues for Strides in Q1 FY25 stood at a quarter-high of $70 million (about Rs 586 crore)

Vinay Rajani of HDFC Securities suggests buying these stocks on July 24

From the low, Nifty recovered 470 points towards 24544 and ended the session at 24479.

Buy & Sell Ideas for June 19; check top stock picks by HDFC Securities

Strides Pharma has retraced more than 61.8 per cent of the entire fall which was seen from the swing high of Rs 425 towards the recent swing low of Rs 312, which indicates negation of a down trend

Strides Pharma Q4 Results: Posts net profit of Rs 10.44 cr, revenue up 5.6%

In the same quarter of the previous fiscal, Strides reported a loss of Rs 13.79 crore. Ebitda grew 4.61 per cent to Rs 204 crore

Strides rallies 9% intraday, hits over 3 year high on healthy Q4 results

Strides Pharma stock price: For FY25, Strides said revenue may grow at 12-15 per cent Y-o-Y and the significant growth will come in H2FY25 based on targeted product launches globally

Strides Pharma Q4 results: Net profit declines 24% to Rs 10.44 crore

Strides Pharma Science Ltd on Wednesday reported a consolidated net profit of Rs 10.44 crore in the fourth quarter ended March 2024. The company, which posted a consolidated net loss of Rs 13.79 crore in the same quarter a year ago, announced a top management rejig with Executive Chairperson & Managing Director Arun Kumar designated as Executive Chairperson while Executive Director Finance & Group CFO Badree Komandur has been elevated as MD and Group CEO. Consolidated total income in the quarter under review stood at Rs 1,070.49 crore as against Rs 1,013.49 crore in the same period a year ago, Strides Pharma Science said in a regulatory filing. Total expenses in the fourth quarter were higher at Rs 984.21 crore as compared to Rs 972.26 crore. The board has recommended a final dividend of Rs 2.50 per equity share of Rs 10 each for the financial year ended March 31, 2024, the filing said. For the year ended March 31, 2024, the consolidated net loss was at Rs 94.31 crore as ...